Product Center
The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-08
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd (Ab&B Bio) has received acceptance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for its application to market the "trivalent influenza virus subunit vaccine for children aged 6-35 months" and the "trivalent influenza virus subunit vaccine for individuals aged 3 years and above". This acceptance marks the final sprint stage of the first domestic full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd (Ab&B Bio) has received acceptance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for its application to market the "trivalent influenza virus subunit vaccine for children aged 6-35 months" and the "trivalent influenza virus subunit vaccine for individuals aged 3 years and above". This acceptance marks the final sprint stage of the first domestic full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-08 11:33
- Views:
Recently, Ab&B Bio-Tech Co., Ltd (Ab&B Bio) has received acceptance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for its application to market the "trivalent influenza virus subunit vaccine for children aged 6-35 months" and the "trivalent influenza virus subunit vaccine for individuals aged 3 years and above". This acceptance marks the final sprint stage of the first domestic full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!

Source: Government Service Website of the Center for Drug Evaluation of the National Medical Products Administration
At present, influenza virus remains one of the most important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross-species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. The WHO Influenza Vaccination Position Paper and the Chinese Center for Disease Control and Prevention's "Technical Guidelines for Influenza Vaccination in China" clearly state that annual influenza vaccination is the most economical and effective measure to prevent influenza, which can significantly reduce the risk of vaccine recipients contracting influenza and developing serious complications.
This year, WHO proposed that the global influenza surveillance network had not detected the B/Yamagata lineage virus since March 2020, and therefore recommended that influenza vaccines should no longer include B/Yamagata lineage components. Ab&B Bio actively responded and acted quickly to complete the market application for the full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, scientifically responding to influenza prevention and control, and providing a variety of influenza vaccine options for society. In addition, this vaccine is the first trivalent influenza virus subunit vaccine in China to achieve a unified dosage form for people aged 6 months and above, improving the convenience of influenza vaccine administration.
Ab&B Bio always insists on not making simple copies and deeply cultivates the field of subunit influenza technology. As of now, the Ab&B Bio subunit influenza vaccine family has covered: quadrivalent influenza virus subunit vaccines for people aged 6-35 months, quadrivalent influenza virus subunit vaccines for people aged 3 years and above, quadrivalent influenza virus subunit vaccines (adjuvanted) for elderly people, trivalent influenza virus subunit vaccines for people aged 6 months and above, trivalent influenza virus subunit vaccines (adjuvanted) for elderly people, and universal subunit influenza vaccines under development. The company adheres to the mission of caring for life and safeguarding health, and covers the needs of various populations with safe, effective, rich, and precise influenza vaccine series products to assist in influenza prevention and control.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us